* EMA to approve Regeneron-Roche cocktail of monoclonal
antibodies
* EU agency to authorise also Celltrion's antibody therapy
* Full marketing authorisations expected this week - source
(Adds details of marketing authorisation)
By Francesco Guarascio
BRUSSELS, Nov 9 (Reuters) - The European Union drugs
regulator is set to authorise the use of two monoclonal
antibodies to treat COVID-19 patients in coming days, two EU
sources told Reuters, in its first approvals of such therapies.
The authorisations would come as the bloc faces a new surge
in infections and hospitalisations despite high vaccination
levels in many countries.
The European Medicines Agency (EMA) will this week give the
green light to the treatment developed by U.S. biotech firm
Regeneron REGN.O and Swiss giant Roche ROG.S , one source
said. The cocktail of antibodies is known as REGEN-COV in the
United States, and is sold elsewhere under the brand name
Ronapreve.
The European regulator will also authorise this week the use
in the EU of the monoclonal antibody Regkirona, developed by
South Korean biotech company Celltrion 091990.KQ , the source
added, asking not to be named because the information is still
confidential.
A second official familiar with the authorisation process
said the approvals were "imminent" but the precise dates had not
been decided.
Both drugs are currently used to treat COVID-19 patients at
risk of developing a severe infection.
The two authorisations would mark an acceleration in the
agency's drug approvals.
Applications for both drugs were submitted in early October
and EMA said then "it could issue an opinion within two months".
Celltrion expects a decision by the end of November, a
spokesperson for the company said.
Roche, who applied in Europe for the approval of Ronapreve,
did not respond to a request for comment.
EMA declined to comment on the approvals but said the two
drugs were being discussed at this week's monthly meetings of
the agency's committee that is responsible for authorisations of
treatments. The meetings started on Monday and will continue
until Thursday.
The review comes after Eli Lilly LLY.N last week withdrew
its application for EU approval of its antibody-based treatment,
citing a lack of demand from EU member states as the bloc
focuses on other suppliers. urn:newsml:reuters.com:*:nL4N2RT3IP
FULL APPROVAL
The only treatment against COVID-19 approved by EMA since
the start of the pandemic is Gilead's GILD.O antiviral
remdesivir.
Regeneron's antibody cocktail was granted emergency
authorisation in the United States last year, and in August
received conditional marketing authorisation in Britain.
The drug is being assessed by EMA under a longer procedure,
which will result in a full marketing authorisation, the sources
said, with one noting that so far there had not been an urgent
medical need to use a speedier procedure.
The EU has immunised over 75% of its adult population,
although in some nations of the 27-country bloc the uptake is
below 40%.
EMA issued recommendations to national authorities in the
first quarter of this year on how to use both drugs before they
were fully approved, paving the way for their use in several
European countries.
The marketing authorisation will allow the use of the drugs
where national agencies had not yet approved them and would
reduce legal risks for governments in countries that are already
administering them.
Last week Regeneron reported higher-than-expected quarterly
revenue on strong demand for its antibody cocktail in the United
States urn:newsml:reuters.com:*:nL4N2RV2F5.
The EU has secured about 55,000 courses of the therapy, a
European Commission spokesperson said in June urn:newsml:reuters.com:*:nL2N2NK1A6.
The bloc has no supply deal with Celltrion, whose antibody
treatment has so far been approved only in South Korea.
(Reporting by Francesco Guarascio @fraguarascio; additional
reporting by Cha Sangmi in Seoul; Editing by Nick Macfie)
((Francesco.Guarascio@thomsonreuters.com;))